Miguel Forte
President at International Society For Cell & GeneTherapy
Profile
Miguel Forte is currently the Director at Alliance for Regenerative Medicine, Associate Professor at the University of Lisbon and the University of Aveiro, and President-Elect at International Society For Cell & Gene Therapy.
He was previously the Chief Executive Officer & Director at Bone Therapeutics SA, Chief Executive Officer at Zelluna Immunotherapy AS, Medical Director at Bristol Myers Squibb Co., Vice President-Medical Affairs at Union de Crédit Pour le Bâtiment SA, Chief Commercialization Officer at International Society for Cellular Therapy, SVP-Clinical Development & Regulatory Affairs at Sangamo Therapeutics France SAS, Chief Medical Officer at Bone Therapeutics SA, and VP-Clinical, Medical & Regulatory Affairs at Nabi Pharmaceuticals.
He holds a doctorate degree from the University of Birmingham and an undergraduate degree from the University of Lisbon.
Miguel Forte active positions
Companies | Position | Start |
---|---|---|
University of Aveiro | Corporate Officer/Principal | - |
University of Lisbon | Corporate Officer/Principal | - |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Director/Board Member | 2018-10-02 |
International Society For Cell & GeneTherapy | President | 2022-05-31 |
Former positions of Miguel Forte
Companies | Position | End |
---|---|---|
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | Chief Executive Officer | 2019-12-18 |
BIOSENIC SA | Chief Tech/Sci/R&D Officer | 2017-10-30 |
BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | 2002-12-31 |
BIOSENIC SA | Chief Executive Officer | - |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | Corporate Officer/Principal | - |
Training of Miguel Forte
University of Birmingham | Doctorate Degree |
University of Lisbon | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Private companies | 8 |
---|---|
Union de Crédit Pour le Bâtiment SA
Union de Crédit Pour le Bâtiment SA Finance/Rental/LeasingFinance Part of BNP Paribas SA, Union de Crédit Pour le Bâtiment SA is a mortgage services provider based in Paris, France. | Finance |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | Commercial Services |
Sangamo Therapeutics France SAS
Sangamo Therapeutics France SAS Miscellaneous Commercial ServicesCommercial Services Sangamo Therapeutics France SAS is a biotechnology company, which engages in developing platforms for T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases. The company was founded on April 12, 2001, and is headquartered in Valbonne-Sophia Antipolis, France. | Commercial Services |
Bone Therapeutics SA
Bone Therapeutics SA Pharmaceuticals: MajorHealth Technology Bone Therapeutics SA is a cell therapy company, which engages in the regenerative therapy addressing for unmet medical needs in the field of bone diseases and orthopedics. Its products include Allob and JTA-004. The company was founded by Jacques Reymann on June 16, 2006 and is headquartered in Gosselies, Belgium. | Health Technology |
Nabi Pharmaceuticals | |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | Health Technology |
International Society For Cell & GeneTherapy |
- Stock Market
- Insiders
- Miguel Forte